News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

June 16, 2020 Apellis Pharmaceuticals to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
June 12, 2020 New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
June 10, 2020 Apellis Announces Investor Conference Call to Discuss Phase 3 PEGASUS Data to be Presented at the 25th Annual Congress of the European Hematology Association (EHA)
June 4, 2020 Apellis Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
May 28, 2020 Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19
May 21, 2020 Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
May 14, 2020 Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress
May 8, 2020 Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference
May 7, 2020 Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
April 29, 2020 Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results